Registered entities
argenx
Reg. No. 0818.292.196Belgium
ARGENX US INC
Reg. No. 364880497United States
Innovation
62 patent families (26 granted) — focus: Chemistry & metallurgy, Human necessities, Physics & computing; filing pace accelerating. Cited 7,465 times.
| Year | Filings |
|---|---|
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 13 |
| 2023 | 27 |
| 2024 | 36 |
| 2025 | 46 |
| 2026 | 10 |
Social engagement
Social engagement: 122.8K social following, 10 posts in the last 12 months — below the industry typical range.
Investor mix
22 investors on record; lead investors include Omnes Capital, VIB, PMV, Forbion; 3 have since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 11 | 50% |
| Private equity | 6 | 27% |
| Bank & private debt | 1 | 5% |
| Other / undisclosed | 4 | 18% |
Hiring activity
Hires occasionally
2 roles tracked across 1 of the last 12 months
11 Dec 2025 · Senior Scientist Computational Chemistry · Ghent
31 Oct 2025 · Director of Corporate Strategy · Ghent
3 Sep 2025 · Director of Discovery & Early Research Strategy · Ghent
11 Feb 2025 · Senior Scientist CMC · Ghent
22 May 2024 · Product Quality Manager · Ghent
Based on job postings tracked across public sources.
Recent activity
26 Jun 2026
Event
International Congress on Neuromuscular Diseases
23 Jun 2026
Product launch
Patient Engagement and Capability Accelerator (PECA)
16 Jun 2026
Event
BIO International 2026